Porous nominated for the Innovation Award Berlin Brandenburg

Early detection of osteoporosis: POROUS GmbH is nominated for the Innovation Award Berlin Brandenburg 2023. Osteoporosis is a chronic widespread disease that affects hundreds…

Read more

NLC Announces Crowdfunding Campaign

NLC Announces Crowdfunding Campaign as part of a larger €10 Million financing round, of which €6.5 million already raised   Amsterdam, 01/10/2023— NLC, the…

Read more

TherageniX and University of Nottingham Awarded £995K

TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration   – Novel non-viral gene delivery…

Read more

IPD secures funding of €2.1M to initiate its first-in-human trials for prosthetic joint infections

PRESS RELEASE Amsterdam, July 20, 2023 IPD B.V. (Implant Preservation Devices), a Netherlands-based start-up specializing in the treatment of prosthetic joint infections, raised €2.1…

Read more

NLC and Australia’s BioCurate announce Strategic Alliance for Commercialization of New Therapies

Amsterdam, July 19, 2023 The two will collaborate on development projects to bring new therapies to market. NLC, the European Healthtech Venture Builder based…

Read more

NLC sluit eerste ronde van het NLC Health Impact Fund

PERSBERICHT 28 juni 2023 NLC, de grootste Healthtech Venture Builder van Europa, kondigt met trots de sluiting van de eerste investeringsronde van het NLC…

Read more

IN THE NEWS: HEALTH IMPACT FUND INITIAL CLOSE

Following the successful initial close of our flagship NLC Health Impact Fund, NLC is proudly featured in the news. Business and financial news outlets…

Read more

NLC announces it has completed the initial close of the NLC Health Impact Fund

June 26, 2023 40 high-impact ventures will receive investments from the largest European healthtech venture builder following the successful initial close of its flagship…

Read more

INTRODUCING OCCLUNOVA: AN IMPLANTABLE DEVICE FOR CHRONIC ATRIAL FIBRILLATION (AF)

PRESS RELEASE June 23, 2023 Founded by NLC, OccluNova is developing an implantable LAA closure device for people with chronic atrial fibrillation (AF) Atrial…

Read more